WO2009072604A1 - 抗nr10抗体、およびその利用 - Google Patents
抗nr10抗体、およびその利用 Download PDFInfo
- Publication number
- WO2009072604A1 WO2009072604A1 PCT/JP2008/072152 JP2008072152W WO2009072604A1 WO 2009072604 A1 WO2009072604 A1 WO 2009072604A1 JP 2008072152 W JP2008072152 W JP 2008072152W WO 2009072604 A1 WO2009072604 A1 WO 2009072604A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- prevention
- useful
- treatment
- inflammatory diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (43)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2008332271A AU2008332271C1 (en) | 2007-12-05 | 2008-12-05 | Anti-NR10 antibody and use thereof |
KR1020167013226A KR20160062207A (ko) | 2008-12-05 | 2008-12-05 | 항nr10 항체 및 그의 이용 |
MX2010006096A MX337081B (es) | 2007-12-05 | 2008-12-05 | Anticuerpo anti-nr10 y su uso. |
BRPI0821110A BRPI0821110B8 (pt) | 2007-12-05 | 2008-12-05 | anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo |
CA2708532A CA2708532C (en) | 2007-12-05 | 2008-12-05 | Anti-il31ra antibody and use thereof |
KR1020167016319A KR20160074019A (ko) | 2007-12-05 | 2008-12-05 | 항nr10 항체 및 그의 이용 |
EP08857126.0A EP2236604B1 (en) | 2007-12-05 | 2008-12-05 | Anti-nr10 antibody and use thereof |
ES08857126.0T ES2585480T3 (es) | 2007-12-05 | 2008-12-05 | Anticuerpo anti-NR10 y uso del mismo |
EP16172648.4A EP3095862B9 (en) | 2007-12-05 | 2008-12-05 | Anti-nr10 antibody and use thereof |
US12/745,781 US20110129459A1 (en) | 2007-12-05 | 2008-12-05 | Anti-nr10 antibody and use thereof |
JP2009544736A JP5682995B2 (ja) | 2007-12-05 | 2008-12-05 | 抗nr10抗体、およびその利用 |
KR1020177031058A KR101840994B1 (ko) | 2007-12-05 | 2008-12-05 | 항nr10 항체 및 그의 이용 |
DK08857126.0T DK2236604T3 (en) | 2007-12-05 | 2008-12-05 | The anti-NR10 antibody and use thereof |
CN200880126539.4A CN101939424B (zh) | 2007-12-05 | 2008-12-05 | 抗nr10抗体及其应用 |
RU2010127292/10A RU2531521C2 (ru) | 2007-12-05 | 2008-12-05 | Антитело против nr10 и его применение |
PCT/JP2009/054941 WO2010064456A1 (ja) | 2008-12-05 | 2009-03-13 | 抗nr10抗体、およびその利用 |
TW098141125A TWI432209B (zh) | 2008-12-05 | 2009-12-02 | Anti-NR10 antibody and its use |
HUE09830463A HUE025958T2 (en) | 2007-12-05 | 2009-12-04 | Anti-NR10 antibody and application |
DK09830463.7T DK2354161T3 (en) | 2008-12-05 | 2009-12-04 | ANTI-NR10 ANTIBODY AND USE THEREOF. |
PT98304637T PT2354161E (pt) | 2008-12-05 | 2009-12-04 | Anticorpo anti-nr10, e a sua utilização |
MX2010007936A MX2010007936A (es) | 2007-12-05 | 2009-12-04 | Anticuerpo anti-nr-10 y su uso. |
EP15172595.9A EP2949672A1 (en) | 2008-12-05 | 2009-12-04 | Anti-nr10 antibody, and use thereof |
EP09830463.7A EP2354161B1 (en) | 2008-12-05 | 2009-12-04 | Anti-nr10 antibody, and use thereof |
PL09830463T PL2354161T3 (pl) | 2008-12-05 | 2009-12-04 | Przeciwciało anty -NR10 i jego zastosowanie |
CA2710264A CA2710264C (en) | 2007-12-05 | 2009-12-04 | Anti-nr10 antibody and use thereof |
KR1020107014700A KR101271323B1 (ko) | 2008-12-05 | 2009-12-04 | 항nr10 항체 및 그의 이용 |
ES09830463.7T ES2552690T3 (es) | 2008-12-05 | 2009-12-04 | Anticuerpo anti-NR10 y uso del mismo |
CN200980106176.2A CN101952318B (zh) | 2007-12-05 | 2009-12-04 | 抗nr10抗体及其应用 |
JP2010507563A JP5139517B2 (ja) | 2008-12-05 | 2009-12-04 | 抗nr10抗体、およびその利用 |
SI200931302T SI2354161T1 (sl) | 2008-12-05 | 2009-12-04 | Anti-NR10 protitelo in njegova uporaba |
PCT/JP2009/070376 WO2010064697A1 (ja) | 2008-12-05 | 2009-12-04 | 抗nr10抗体、およびその利用 |
MYPI2010002989A MY154715A (en) | 2008-12-05 | 2009-12-04 | Anti-nr10 antibody and use thereof |
BRPI0906478A BRPI0906478B8 (pt) | 2008-12-05 | 2009-12-04 | anticorpo anti-nr10, seu uso e composição farmacêutica que o compreende |
RU2010126078/10A RU2487136C2 (ru) | 2008-12-05 | 2009-12-04 | Антитело против nr10 и его применение |
AU2009323249A AU2009323249B2 (en) | 2007-12-05 | 2009-12-04 | Anti-NR10 antibody, and use thereof |
US12/809,138 US8575317B2 (en) | 2007-12-05 | 2009-12-04 | Anti-NR10 antibody and use thereof |
HK11105170.8A HK1151048A1 (en) | 2008-12-05 | 2011-05-24 | Anti-nr 10 antibody, and use thereof nr10 |
US14/047,316 US9399680B2 (en) | 2007-12-05 | 2013-10-07 | Nucleic acids encoding anti-NR10 antibodies |
US14/340,883 US20150175704A1 (en) | 2007-12-05 | 2014-07-25 | Anti-nr10 antibody and use thereof |
HRP20151215TT HRP20151215T1 (hr) | 2007-12-05 | 2015-11-12 | Anti-nr10 protutijela i njihova uporaba |
US16/560,143 US20200002429A1 (en) | 2007-12-05 | 2019-09-04 | Anti-nr10 antibody and use thereof |
US17/975,865 US20230183363A1 (en) | 2007-12-05 | 2022-10-28 | Anti-nr10 antibody and use thereof |
US18/661,829 US20240294653A1 (en) | 2007-12-05 | 2024-05-13 | Anti-nr10 antibody and use thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007-315143 | 2007-12-05 | ||
JP2007315143 | 2007-12-05 | ||
JP2008247425 | 2008-09-26 | ||
JP2008-247425 | 2008-09-26 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/745,781 A-371-Of-International US20110129459A1 (en) | 2007-12-05 | 2008-12-05 | Anti-nr10 antibody and use thereof |
US14/340,883 Continuation US20150175704A1 (en) | 2007-12-05 | 2014-07-25 | Anti-nr10 antibody and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009072604A1 true WO2009072604A1 (ja) | 2009-06-11 |
Family
ID=40717782
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2008/072152 WO2009072604A1 (ja) | 2007-12-05 | 2008-12-05 | 抗nr10抗体、およびその利用 |
Country Status (17)
Country | Link |
---|---|
US (7) | US20110129459A1 (ja) |
EP (2) | EP3095862B9 (ja) |
JP (1) | JP5682995B2 (ja) |
KR (3) | KR101643005B1 (ja) |
CN (2) | CN101939424B (ja) |
AU (2) | AU2008332271C1 (ja) |
BR (1) | BRPI0821110B8 (ja) |
CA (2) | CA2708532C (ja) |
DK (1) | DK2236604T3 (ja) |
ES (2) | ES2585480T3 (ja) |
HR (1) | HRP20151215T1 (ja) |
HU (1) | HUE025958T2 (ja) |
MX (2) | MX337081B (ja) |
MY (1) | MY177564A (ja) |
RU (1) | RU2531521C2 (ja) |
TW (2) | TW201634479A (ja) |
WO (1) | WO2009072604A1 (ja) |
Cited By (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101952318A (zh) * | 2007-12-05 | 2011-01-19 | 中外制药株式会社 | 抗nr10抗体及其应用 |
WO2011055550A1 (ja) | 2009-11-05 | 2011-05-12 | 国立大学法人大阪大学 | 自己免疫疾患又はアレルギー治療剤とそのスクリーニング方法 |
WO2011090088A1 (ja) | 2010-01-20 | 2011-07-28 | 中外製薬株式会社 | 安定化抗体含有溶液製剤 |
EP2354161A1 (en) * | 2008-12-05 | 2011-08-10 | Chugai Seiyaku Kabushiki Kaisha | Anti-nr10 antibody, and use thereof |
WO2011143318A3 (en) * | 2010-05-11 | 2012-01-05 | Aveo Pharmaceuticals, Inc. | Anti-fgfr2 antibodies |
JPWO2010064697A1 (ja) * | 2008-12-05 | 2012-05-10 | 中外製薬株式会社 | 抗nr10抗体、およびその利用 |
WO2012091124A1 (ja) | 2010-12-28 | 2012-07-05 | 中外製薬株式会社 | 動物細胞の培養方法 |
WO2013012022A1 (ja) | 2011-07-19 | 2013-01-24 | 中外製薬株式会社 | アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤 |
WO2013031237A1 (en) | 2011-09-01 | 2013-03-07 | Chugai Seiyaku Kabushiki Kaisha | Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration |
US8431127B2 (en) | 2007-12-05 | 2013-04-30 | Chugai Seiyaku Kabushiki Kaisha | Method for treating pruritus comprising administering an NR10 antagonist |
JPWO2011108714A1 (ja) * | 2010-03-04 | 2013-06-27 | 中外製薬株式会社 | 抗体定常領域改変体 |
US8562991B2 (en) | 2008-09-26 | 2013-10-22 | Chugai Seiyaku Kabushiki Kaisha | Antibody molecules that bind to IL-6 receptor |
US9028821B2 (en) | 2006-06-08 | 2015-05-12 | Chugai Seiyaku Kabushiki Kaisha | Method of treating an inflammatory disease comprising administering an NR 10 antibody antagonist |
WO2015099165A1 (ja) | 2013-12-27 | 2015-07-02 | 中外製薬株式会社 | 等電点の低い抗体の精製方法 |
US9096651B2 (en) | 2007-09-26 | 2015-08-04 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
US9228017B2 (en) | 2009-03-19 | 2016-01-05 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
US9670269B2 (en) | 2006-03-31 | 2017-06-06 | Chugai Seiyaku Kabushiki Kaisha | Methods of modifying antibodies for purification of bispecific antibodies |
US9688762B2 (en) | 2007-09-26 | 2017-06-27 | Chugai Sciyaku Kabushiki Kaisha | Modified antibody constant region |
US9868948B2 (en) | 2008-04-11 | 2018-01-16 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
US10011858B2 (en) | 2005-03-31 | 2018-07-03 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
US10150808B2 (en) | 2009-09-24 | 2018-12-11 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant regions |
JP2019504060A (ja) * | 2016-01-08 | 2019-02-14 | オンコバイオロジクス,インコーポレイティド | モノクローナル抗体のアイソフォームを分離するための方法 |
US10253091B2 (en) | 2009-03-19 | 2019-04-09 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
WO2019225568A1 (ja) | 2018-05-21 | 2019-11-28 | 中外製薬株式会社 | ガラス容器に封入された凍結乾燥製剤 |
WO2019230725A1 (ja) | 2018-05-28 | 2019-12-05 | 中外製薬株式会社 | 充填ノズル |
US10544227B2 (en) | 2015-04-14 | 2020-01-28 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising IL-31 antagonist as active ingredient |
US10604561B2 (en) | 2016-09-16 | 2020-03-31 | Chugai Seiyaku Kabushiki Kaisha | Anti-dengue virus antibodies, polypeptides containing variant Fc regions, and methods of use |
US10774148B2 (en) | 2015-02-27 | 2020-09-15 | Chugai Seiyaku Kabushiki Kaisha | Composition for treating IL-6-related diseases |
JP6845973B1 (ja) * | 2019-11-20 | 2021-03-24 | 中外製薬株式会社 | 抗体含有製剤 |
US11046784B2 (en) | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
US11124576B2 (en) | 2013-09-27 | 2021-09-21 | Chungai Seiyaku Kabushiki Kaisha | Method for producing polypeptide heteromultimer |
US11142587B2 (en) | 2015-04-01 | 2021-10-12 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide hetero-oligomer |
KR20210145295A (ko) | 2015-04-14 | 2021-12-01 | 추가이 세이야쿠 가부시키가이샤 | Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물 |
WO2022025030A1 (ja) | 2020-07-28 | 2022-02-03 | 中外製薬株式会社 | 新規改変型抗体を含む、針シールドを備えた針付プレフィルドシリンジ製剤 |
WO2022049614A1 (ja) | 2020-09-01 | 2022-03-10 | 中外製薬株式会社 | Il-31アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び/又は治療用医薬組成物 |
EP4056993A1 (en) | 2014-08-20 | 2022-09-14 | Chugai Seiyaku Kabushiki Kaisha | Method for measuring viscosity of protein solution |
WO2023058723A1 (ja) | 2021-10-08 | 2023-04-13 | 中外製薬株式会社 | プレフィルドシリンジ製剤の調製方法 |
US11649262B2 (en) | 2015-12-28 | 2023-05-16 | Chugai Seiyaku Kabushiki Kaisha | Method for promoting efficiency of purification of Fc region-containing polypeptide |
WO2023120561A1 (ja) * | 2021-12-22 | 2023-06-29 | 中外製薬株式会社 | 生物活性が低下した抗体バリアント |
US11851486B2 (en) | 2017-05-02 | 2023-12-26 | National Center Of Neurology And Psychiatry | Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils |
US11891432B2 (en) | 2018-03-15 | 2024-02-06 | Chugai Seiyaku Kabushiki Kaisha | Anti-dengue virus antibodies having cross-reactivity to Zika virus and methods of use |
US11891434B2 (en) | 2010-11-30 | 2024-02-06 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2869316C (en) | 2012-05-09 | 2016-12-20 | Eli Lilly And Company | Anti-c-met antibodies |
US9758591B2 (en) | 2012-08-24 | 2017-09-12 | The Regents Of The University Of California | Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis |
DK3221346T3 (da) | 2014-11-21 | 2020-10-12 | Bristol Myers Squibb Co | Antistoffer omfattende modificerede konstante områder af tungkæden |
CA2968357A1 (en) | 2014-11-21 | 2016-05-26 | Bristol-Myers Squibb Company | Antibodies against cd73 and uses thereof |
CN105331703B (zh) * | 2015-11-16 | 2018-08-17 | 中国农业科学院北京畜牧兽医研究所 | 一种鉴定或辅助鉴定猪100kg体重眼肌面积的方法及其专用试剂盒 |
MY196869A (en) | 2016-06-27 | 2023-05-05 | Univ California | Cancer treatment combinations |
CN113637073B (zh) * | 2020-05-11 | 2024-04-12 | 上海赛比曼生物科技有限公司 | Bcma抗体及其制备和应用 |
MX2024002584A (es) * | 2021-08-30 | 2024-07-02 | Galderma Holding SA | Tratamientos para la dermatitis atopica. |
Citations (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
EP0058481A1 (en) | 1981-02-16 | 1982-08-25 | Zeneca Limited | Continuous release pharmaceutical compositions |
EP0125023A1 (en) | 1983-04-08 | 1984-11-14 | Genentech, Inc. | Recombinant immunoglobulin preparations, methods for their preparation, DNA sequences, expression vectors and recombinant host cells therefor |
EP0133988A2 (de) | 1983-08-02 | 1985-03-13 | Hoechst Aktiengesellschaft | Regulatorische Peptide enthaltende pharmazeutische Präparate mit protrahierter Freisetzung und Verfahren zu deren Herstellung |
EP0239400A2 (en) | 1986-03-27 | 1987-09-30 | Medical Research Council | Recombinant antibodies and methods for their production |
JPH0159878B2 (ja) | 1982-05-21 | 1989-12-20 | Yunibaashitei Obu Karifuorunia | |
EP0404097A2 (de) | 1989-06-22 | 1990-12-27 | BEHRINGWERKE Aktiengesellschaft | Bispezifische und oligospezifische, mono- und oligovalente Rezeptoren, ihre Herstellung und Verwendung |
US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
WO1992001047A1 (en) | 1990-07-10 | 1992-01-23 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5156840A (en) | 1982-03-09 | 1992-10-20 | Cytogen Corporation | Amine-containing porphyrin derivatives |
WO1992020791A1 (en) | 1990-07-10 | 1992-11-26 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1993006213A1 (en) | 1991-09-23 | 1993-04-01 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
WO1993011161A1 (en) | 1991-11-25 | 1993-06-10 | Enzon, Inc. | Multivalent antigen-binding proteins |
WO1993011236A1 (en) | 1991-12-02 | 1993-06-10 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1993019172A1 (en) | 1992-03-24 | 1993-09-30 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
WO1994025585A1 (en) | 1993-04-26 | 1994-11-10 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1995001438A1 (en) | 1993-06-30 | 1995-01-12 | Medical Research Council | Sbp members with a chemical moiety covalently bound within the binding site; production and selection thereof |
WO1995015388A1 (en) | 1993-12-03 | 1995-06-08 | Medical Research Council | Recombinant binding proteins and peptides |
WO1996002576A1 (fr) | 1994-07-13 | 1996-02-01 | Chugai Seiyaku Kabushiki Kaisha | Anticorps humain reconstitue contre l'interleukine-8 humaine |
WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1998013388A1 (fr) | 1996-09-26 | 1998-04-02 | Chugai Seiyaku Kabushiki Kaisha | Anticorps contre les peptides lies a la parathormone humaine |
WO1998046777A1 (fr) | 1997-04-11 | 1998-10-22 | Centre National De La Recherche Scientifique (Cnrs) | Preparation de recepteurs membranaires a partir de baculovirus extracellulaires |
WO2000075314A1 (fr) | 1999-06-02 | 2000-12-14 | Chugai Research Institute For Molecular Medicine, Inc. | Proteine receptrice d'hemopoietine |
WO2003104453A1 (ja) | 2002-06-05 | 2003-12-18 | 中外製薬株式会社 | 抗体作製方法 |
WO2005054467A1 (ja) | 2003-12-03 | 2005-06-16 | Chugai Seiyaku Kabushiki Kaisha | 哺乳類βアクチンプロモーターを利用した発現系 |
WO2006070286A2 (en) * | 2004-12-28 | 2006-07-06 | Innate Pharma S.A. | Monoclonal antibodies against nkg2a |
Family Cites Families (119)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59162441U (ja) | 1983-04-14 | 1984-10-31 | 千代田紙業株式会社 | 吹込口を有する重包包装 |
US5260203A (en) * | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US5670373A (en) * | 1988-01-22 | 1997-09-23 | Kishimoto; Tadamitsu | Antibody to human interleukin-6 receptor |
US5322678A (en) * | 1988-02-17 | 1994-06-21 | Neorx Corporation | Alteration of pharmacokinetics of proteins by charge modification |
DE69229482T2 (de) * | 1991-04-25 | 1999-11-18 | Chugai Seiyaku K.K., Tokio/Tokyo | Rekombinierte humane antikörper gegen den humanen interleukin 6-rezeptor |
US6136310A (en) | 1991-07-25 | 2000-10-24 | Idec Pharmaceuticals Corporation | Recombinant anti-CD4 antibodies for human therapy |
JPH0767688B2 (ja) | 1992-01-21 | 1995-07-26 | 近畿コンクリート工業株式会社 | Pcコンクリートパネル |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
BR9204244A (pt) | 1992-10-26 | 1994-05-03 | Cofap | Ferro fundido cinzento |
CA2149025A1 (en) | 1992-12-01 | 1994-06-09 | Man Sung Co | Humanized antibodies reactive with l-selectin |
IL107742A0 (en) | 1993-11-24 | 1994-02-27 | Yeda Res & Dev | Chemically-modified binding proteins |
DE4419399C1 (de) | 1994-06-03 | 1995-03-09 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von heterologen bispezifischen Antikörpern |
US5945311A (en) | 1994-06-03 | 1999-08-31 | GSF--Forschungszentrumfur Umweltund Gesundheit | Method for producing heterologous bi-specific antibodies |
US8017121B2 (en) * | 1994-06-30 | 2011-09-13 | Chugai Seiyaku Kabushika Kaisha | Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component |
ES2384222T3 (es) | 1994-10-07 | 2012-07-02 | Chugai Seiyaku Kabushiki Kaisha | Inhibición del crecimiento anómalo de células sinoviales utilizando un antagonista de IL-6 como principio activo |
CA2203182C (en) | 1994-10-21 | 2009-11-24 | Asao Katsume | Remedy for diseases caused by il-6 production |
FR2729855A1 (fr) | 1995-01-26 | 1996-08-02 | Oreal | Utilisation d'un antagoniste de cgrp dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue |
US5876950A (en) | 1995-01-26 | 1999-03-02 | Bristol-Myers Squibb Company | Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
WO1997010354A1 (en) | 1995-09-11 | 1997-03-20 | Kyowa Hakko Kogyo Co., Ltd. | ANTIBODY AGAINTS α-CHAIN OF HUMAN INTERLEUKIN 5 RECEPTOR |
US6211150B1 (en) | 1996-07-19 | 2001-04-03 | Amgen Inc. | Analogs of cationic proteins |
US7365166B2 (en) * | 1997-04-07 | 2008-04-29 | Genentech, Inc. | Anti-VEGF antibodies |
US20020187150A1 (en) * | 1997-08-15 | 2002-12-12 | Chugai Seiyaku Kabushiki Kaisha | Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient |
CA2305712A1 (en) * | 1997-10-03 | 1999-04-15 | Chugai Seiyaku Kabushiki Kaisha | Natural humanized antibody |
PT1074268E (pt) * | 1998-03-17 | 2008-02-28 | Chugai Pharmaceutical Co Ltd | Agentes profilácticos ou terapêuticos para doenças intestinais inflamatórias contendo anticorpos antagonistas do receptor il-6 |
DK1069185T3 (da) | 1998-04-03 | 2011-06-27 | Chugai Pharmaceutical Co Ltd | Humaniseret antistof mod human vævsfaktor (TF) og fremgangsmåde til at konstruere humaniseret antistof |
BR9910568A (pt) | 1998-04-30 | 2001-09-11 | Tanox Inc | Anticorpos agonistas de receptor de g-csf e processo de seleção para os mesmos |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
FR2780062B1 (fr) | 1998-06-17 | 2000-07-28 | Rhone Poulenc Rorer Sa | Anticorps monoclonaux diriges contre la proteine g3bp, et leurs utilisations |
CA2341029A1 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
KR100483494B1 (ko) * | 1998-12-01 | 2005-04-15 | 프로테인 디자인 랩스 인코포레이티드 | 감마 인터페론에 대한 인간화 항체 |
CN1202128C (zh) | 1998-12-08 | 2005-05-18 | 拜奥威神有限公司 | 修饰蛋白的免疫原性 |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US6972125B2 (en) | 1999-02-12 | 2005-12-06 | Genetics Institute, Llc | Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith |
SK782002A3 (en) * | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
SE9903895D0 (sv) | 1999-10-28 | 1999-10-28 | Active Biotech Ab | Novel compounds |
US20020034537A1 (en) | 2000-05-03 | 2002-03-21 | Brita Schulze | Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites |
US20030096339A1 (en) * | 2000-06-26 | 2003-05-22 | Sprecher Cindy A. | Cytokine receptor zcytor17 |
WO2002036165A1 (fr) * | 2000-10-27 | 2002-05-10 | Chugai Seiyaku Kabushiki Kaisha | Agent à base d'antagoniste d'il-6, faisant baisser le niveau des mmp-3 dans le sang |
AU2002248571B2 (en) | 2001-03-07 | 2007-01-18 | Merck Patent Gmbh | Expression technology for proteins containing a hybrid isotype antibody moiety |
UA80091C2 (en) | 2001-04-02 | 2007-08-27 | Chugai Pharmaceutical Co Ltd | Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist |
US20040234524A1 (en) | 2001-04-05 | 2004-11-25 | Toshimitsu Uede | Anti-osteopontin antibody and use thereof |
EA006705B1 (ru) | 2001-04-13 | 2006-02-24 | Байоджен Айдек Ма Инк. | Антитела против vla-1 |
EP2208784B1 (en) | 2001-06-22 | 2013-01-02 | Chugai Seiyaku Kabushiki Kaisha | Cell proliferation inhibitors containing anti-glypican 3 antibody |
PT1576112E (pt) | 2002-01-18 | 2012-05-25 | Zymogenetics Inc | Multímeros de receptor de citocina zcytor17 |
ES2351678T3 (es) * | 2002-01-18 | 2011-02-09 | Zymogenetics, Inc. | Ligando de citocina para el tratamiento de asma e hiper-sensibilidad de las vías respiratorias . |
US20050130224A1 (en) | 2002-05-31 | 2005-06-16 | Celestar Lexico- Sciences, Inc. | Interaction predicting device |
AU2003256266A1 (en) | 2002-06-12 | 2003-12-31 | Genencor International, Inc. | Methods and compositions for milieu-dependent binding of a targeted agent to a target |
TW200407335A (en) * | 2002-07-22 | 2004-05-16 | Chugai Pharmaceutical Co Ltd | Non-neutralizing antibody to inhibit the inactivation of activated protein C |
US20040086979A1 (en) | 2002-08-15 | 2004-05-06 | Dongxiao Zhang | Humanized rabbit antibodies |
US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
KR100499989B1 (ko) | 2002-12-27 | 2005-07-07 | 네오바이오다임 주식회사 | 아사이알로 α1-산 당단백질에 대한 단일클론 항체, 이 항체를 포함하는 아사이알로 α1-산 당단백질에 대한 단일클론 항체, 이 항체를 포함하는 면역크로마토그래피 스트립 및 이 스트립를 이용한 아사이알로 α1-산 당단백질 측정방법 |
WO2004068931A2 (en) | 2003-02-07 | 2004-08-19 | Protein Design Labs Inc. | Amphiregulin antibodies and their use to treat cancer and psoriasis |
US20040223970A1 (en) * | 2003-02-28 | 2004-11-11 | Daniel Afar | Antibodies against SLC15A2 and uses thereof |
ES2527414T3 (es) | 2003-03-04 | 2015-01-23 | Alexion Pharmaceuticals, Inc. | Método para el tratamiento de una enfermedad autoinmune mediante la inducción de la presentación de antígeno mediante células presentadoras de antígeno que inducen tolerancia |
EA009026B1 (ru) | 2003-03-24 | 2007-10-26 | Займоджинетикс, Инк. | Антитела против il-22ra, их партнеры по связыванию и способы их применения при воспалениях |
GB2401040A (en) | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
WO2004113387A2 (en) | 2003-06-24 | 2004-12-29 | Merck Patent Gmbh | Tumour necrosis factor receptor molecules with reduced immunogenicity |
WO2005035753A1 (ja) | 2003-10-10 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | 機能蛋白質を代替する二重特異性抗体 |
EP1693448A4 (en) * | 2003-10-14 | 2008-03-05 | Chugai Pharmaceutical Co Ltd | DOUBLE SPECIFICITY ANTIBODY FOR FUNCTIONAL PROTEIN SUBSTITUTION |
JP2008504002A (ja) | 2003-11-12 | 2008-02-14 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 新生児Fcレセプター(FcRn)結合ポリペプチド改変体、ダイマーFc結合タンパク質、およびそれらに関連する方法 |
EP1701979A2 (en) | 2003-12-03 | 2006-09-20 | Xencor, Inc. | Optimized antibodies that target the epidermal growth factor receptor |
AR048210A1 (es) | 2003-12-19 | 2006-04-12 | Chugai Pharmaceutical Co Ltd | Un agente preventivo para la vasculitis. |
MX370489B (es) | 2004-01-09 | 2019-12-16 | Pfizer | Anticuerpos contra madcam. |
WO2005092925A2 (en) * | 2004-03-24 | 2005-10-06 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
AR048335A1 (es) | 2004-03-24 | 2006-04-19 | Chugai Pharmaceutical Co Ltd | Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo |
AR049390A1 (es) | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
JP2008504289A (ja) * | 2004-06-25 | 2008-02-14 | メディミューン,インコーポレーテッド | 部位特異的突然変異誘発による哺乳動物細胞における組換え抗体の産生の増加 |
EP2940043A1 (en) | 2004-07-15 | 2015-11-04 | Xencor, Inc. | Optimized fc variants |
WO2006030200A1 (en) | 2004-09-14 | 2006-03-23 | National Institute For Biological Standards And Control | Vaccine |
US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
KR101370253B1 (ko) * | 2004-10-22 | 2014-03-05 | 암젠 인크 | 재조합 항체의 재접힘 방법 |
CA2587766A1 (en) * | 2004-11-10 | 2007-03-01 | Macrogenics, Inc. | Engineering fc antibody regions to confer effector function |
US20090061485A1 (en) * | 2004-12-22 | 2009-03-05 | Chugai Seiyaku Kabushiki Kaisha | Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited |
EP1833510A4 (en) | 2004-12-27 | 2010-02-10 | Progenics Pharmaceuticals Neva | ORAL ADMINISTRATION ANTITOXIN ANTIBODIES AND METHODS OF MAKING AND USING THE SAME |
JP4986633B2 (ja) | 2005-01-12 | 2012-07-25 | 協和発酵キリン株式会社 | 安定化されたヒトIgG2およびIgG3抗体 |
AU2006204791A1 (en) * | 2005-01-12 | 2006-07-20 | Xencor, Inc | Antibodies and Fc fusion proteins with altered immunogenicity |
MX2007009718A (es) | 2005-02-14 | 2007-09-26 | Zymogenetics Inc | Metodos para tratar trastornos cutaneos utilizando un antagonista il-31ra. |
WO2006106905A1 (ja) | 2005-03-31 | 2006-10-12 | Chugai Seiyaku Kabushiki Kaisha | 会合制御によるポリペプチド製造方法 |
EP1876236B9 (en) * | 2005-04-08 | 2015-02-25 | Chugai Seiyaku Kabushiki Kaisha | Antibody substituting for function of blood coagulation factor viii |
UY29504A1 (es) | 2005-04-29 | 2006-10-31 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos. |
US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
WO2007143231A2 (en) | 2006-01-10 | 2007-12-13 | Zymogenetics, Inc. | Methods of treating pain and inflammation in neuronal tissue using il-31 antagonists |
US20070134234A1 (en) | 2005-09-29 | 2007-06-14 | Viral Logic Systems Technology Corp. | Immunomodulatory compositions and uses therefor |
JP5014143B2 (ja) | 2005-10-14 | 2012-08-29 | 学校法人福岡大学 | 膵島移植における移植膵島障害抑制剤 |
AR058135A1 (es) | 2005-10-21 | 2008-01-23 | Chugai Pharmaceutical Co Ltd | Agentes para el tratamiento de cardiopatias |
SG10201400426XA (en) * | 2006-01-12 | 2014-07-30 | Alexion Pharma Inc | Antibodies to ox-2/cd200 and uses thereof |
EP2325209A3 (en) * | 2006-03-23 | 2011-08-03 | BioArtic Neuroscience AB | Improved protofibril selective antibodies and the use thereof |
US8048421B2 (en) | 2006-03-23 | 2011-11-01 | Kyowa Hakko Kirin Co., Ltd. | Agonist antibody to human thrombopoietin receptor |
US11046784B2 (en) | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
EP4218801A3 (en) | 2006-03-31 | 2023-08-23 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for purifying bispecific antibody |
JP5754875B2 (ja) * | 2006-04-07 | 2015-07-29 | 国立大学法人大阪大学 | 筋再生促進剤 |
CN103272232B (zh) | 2006-06-08 | 2018-07-24 | 中外制药株式会社 | 炎性疾病的预防或治疗药 |
WO2007147122A2 (en) * | 2006-06-15 | 2007-12-21 | The Board Of Trustees Of The University Of Arkansas | Monoclonal antibodies that selectively recognize methamphetamine and methamphetamine like compounds |
US20100034194A1 (en) | 2006-10-11 | 2010-02-11 | Siemens Communications Inc. | Eliminating unreachable subscribers in voice-over-ip networks |
WO2008092117A2 (en) | 2007-01-25 | 2008-07-31 | Xencor, Inc. | Immunoglobulins with modifications in the fcr binding region |
WO2008100995A1 (en) * | 2007-02-14 | 2008-08-21 | Vaccinex, Inc. | Humanized anti-cd100 antibodies |
AR065420A1 (es) | 2007-02-23 | 2009-06-03 | Schering Corp | Anticuerpos anti-il-23 p19 de ingenieria |
WO2008114733A1 (ja) * | 2007-03-16 | 2008-09-25 | Kyowa Hakko Kirin Co., Ltd. | 抗Claudin-4抗体 |
GB0708002D0 (en) | 2007-04-25 | 2007-06-06 | Univ Sheffield | Antibodies |
WO2008145141A1 (en) | 2007-05-31 | 2008-12-04 | Genmab A/S | Method for extending the half-life of exogenous or endogenous soluble molecules |
EP2031064A1 (de) | 2007-08-29 | 2009-03-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verfahren zur Steigerung von Proteintitern |
ES2687808T3 (es) | 2007-09-26 | 2018-10-29 | Chugai Seiyaku Kabushiki Kaisha | Región constante de anticuerpo modificado |
SI2202245T1 (sl) | 2007-09-26 | 2016-10-28 | Chugai Seiyaku Kabushiki Kaisha | Postopek modificiranja izoelektrične točke protitelesa preko aminokislinske substitucije v CDR |
MX2010003329A (es) | 2007-09-26 | 2010-04-27 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti-receptor de il-6. |
AR066172A1 (es) * | 2007-09-28 | 2009-07-29 | Chugai Pharmaceutical Co Ltd | Metodo para la preparacion de un anticuerpo antiglipicano 3 con modulada cinetica plasmatica mediante variacion de la semivida plasmatica. |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
EP2241332A4 (en) | 2007-12-05 | 2011-01-26 | Chugai Pharmaceutical Co Ltd | THERAPEUTIC AGENT AGAINST PRITURE |
KR101643005B1 (ko) | 2007-12-05 | 2016-07-28 | 추가이 세이야쿠 가부시키가이샤 | 항nr10 항체 및 그의 이용 |
PL2250279T3 (pl) | 2008-02-08 | 2016-11-30 | Przeciwciała anty-ifnar1 o zmniejszonym powinowactwie do liganda fc | |
PL2275443T3 (pl) * | 2008-04-11 | 2016-05-31 | Chugai Pharmaceutical Co Ltd | Cząsteczka wiążąca antygen zdolna do wiązania dwóch lub więcej cząsteczek antygenu w sposób powtarzalny |
JP2011519279A (ja) | 2008-05-01 | 2011-07-07 | アムジエン・インコーポレーテツド | 抗ヘプシジン抗体及び使用の方法 |
TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
JP5717624B2 (ja) * | 2009-03-19 | 2015-05-13 | 中外製薬株式会社 | 抗体定常領域改変体 |
TWI544077B (zh) | 2009-03-19 | 2016-08-01 | Chugai Pharmaceutical Co Ltd | Antibody constant region change body |
EP2481752B1 (en) * | 2009-09-24 | 2016-11-09 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant regions |
WO2011108714A1 (ja) * | 2010-03-04 | 2011-09-09 | 中外製薬株式会社 | 抗体定常領域改変体 |
BR112012022917A2 (pt) | 2010-03-11 | 2017-01-10 | Pfizer | anticorpos com ligação a antígeno dependente de ph |
-
2008
- 2008-12-05 KR KR1020107014698A patent/KR101643005B1/ko active IP Right Grant
- 2008-12-05 ES ES08857126.0T patent/ES2585480T3/es active Active
- 2008-12-05 MX MX2010006096A patent/MX337081B/es active IP Right Grant
- 2008-12-05 DK DK08857126.0T patent/DK2236604T3/en active
- 2008-12-05 US US12/745,781 patent/US20110129459A1/en not_active Abandoned
- 2008-12-05 MY MYPI2010002565A patent/MY177564A/en unknown
- 2008-12-05 BR BRPI0821110A patent/BRPI0821110B8/pt active IP Right Grant
- 2008-12-05 CN CN200880126539.4A patent/CN101939424B/zh active Active
- 2008-12-05 TW TW105118884A patent/TW201634479A/zh unknown
- 2008-12-05 EP EP16172648.4A patent/EP3095862B9/en active Active
- 2008-12-05 CA CA2708532A patent/CA2708532C/en active Active
- 2008-12-05 WO PCT/JP2008/072152 patent/WO2009072604A1/ja active Application Filing
- 2008-12-05 AU AU2008332271A patent/AU2008332271C1/en active Active
- 2008-12-05 KR KR1020167016319A patent/KR20160074019A/ko active Application Filing
- 2008-12-05 TW TW097147385A patent/TWI548418B/zh active
- 2008-12-05 EP EP08857126.0A patent/EP2236604B1/en active Active
- 2008-12-05 ES ES16172648T patent/ES2834741T3/es active Active
- 2008-12-05 KR KR1020177031058A patent/KR101840994B1/ko active IP Right Grant
- 2008-12-05 RU RU2010127292/10A patent/RU2531521C2/ru active
- 2008-12-05 JP JP2009544736A patent/JP5682995B2/ja active Active
-
2009
- 2009-12-04 US US12/809,138 patent/US8575317B2/en active Active
- 2009-12-04 HU HUE09830463A patent/HUE025958T2/en unknown
- 2009-12-04 AU AU2009323249A patent/AU2009323249B2/en active Active
- 2009-12-04 CA CA2710264A patent/CA2710264C/en active Active
- 2009-12-04 CN CN200980106176.2A patent/CN101952318B/zh active Active
- 2009-12-04 MX MX2010007936A patent/MX2010007936A/es active IP Right Grant
-
2013
- 2013-10-07 US US14/047,316 patent/US9399680B2/en active Active
-
2014
- 2014-07-25 US US14/340,883 patent/US20150175704A1/en not_active Abandoned
-
2015
- 2015-11-12 HR HRP20151215TT patent/HRP20151215T1/hr unknown
-
2019
- 2019-09-04 US US16/560,143 patent/US20200002429A1/en not_active Abandoned
-
2022
- 2022-10-28 US US17/975,865 patent/US20230183363A1/en not_active Abandoned
-
2024
- 2024-05-13 US US18/661,829 patent/US20240294653A1/en active Pending
Patent Citations (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
EP0058481A1 (en) | 1981-02-16 | 1982-08-25 | Zeneca Limited | Continuous release pharmaceutical compositions |
US5156840A (en) | 1982-03-09 | 1992-10-20 | Cytogen Corporation | Amine-containing porphyrin derivatives |
JPH0159878B2 (ja) | 1982-05-21 | 1989-12-20 | Yunibaashitei Obu Karifuorunia | |
EP0125023A1 (en) | 1983-04-08 | 1984-11-14 | Genentech, Inc. | Recombinant immunoglobulin preparations, methods for their preparation, DNA sequences, expression vectors and recombinant host cells therefor |
EP0133988A2 (de) | 1983-08-02 | 1985-03-13 | Hoechst Aktiengesellschaft | Regulatorische Peptide enthaltende pharmazeutische Präparate mit protrahierter Freisetzung und Verfahren zu deren Herstellung |
US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
EP0239400A2 (en) | 1986-03-27 | 1987-09-30 | Medical Research Council | Recombinant antibodies and methods for their production |
EP0404097A2 (de) | 1989-06-22 | 1990-12-27 | BEHRINGWERKE Aktiengesellschaft | Bispezifische und oligospezifische, mono- und oligovalente Rezeptoren, ihre Herstellung und Verwendung |
WO1992001047A1 (en) | 1990-07-10 | 1992-01-23 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1992020791A1 (en) | 1990-07-10 | 1992-11-26 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1993006213A1 (en) | 1991-09-23 | 1993-04-01 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
WO1993011161A1 (en) | 1991-11-25 | 1993-06-10 | Enzon, Inc. | Multivalent antigen-binding proteins |
WO1993011236A1 (en) | 1991-12-02 | 1993-06-10 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1993019172A1 (en) | 1992-03-24 | 1993-09-30 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
WO1994025585A1 (en) | 1993-04-26 | 1994-11-10 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1995001438A1 (en) | 1993-06-30 | 1995-01-12 | Medical Research Council | Sbp members with a chemical moiety covalently bound within the binding site; production and selection thereof |
WO1995015388A1 (en) | 1993-12-03 | 1995-06-08 | Medical Research Council | Recombinant binding proteins and peptides |
WO1996002576A1 (fr) | 1994-07-13 | 1996-02-01 | Chugai Seiyaku Kabushiki Kaisha | Anticorps humain reconstitue contre l'interleukine-8 humaine |
WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1998013388A1 (fr) | 1996-09-26 | 1998-04-02 | Chugai Seiyaku Kabushiki Kaisha | Anticorps contre les peptides lies a la parathormone humaine |
WO1998046777A1 (fr) | 1997-04-11 | 1998-10-22 | Centre National De La Recherche Scientifique (Cnrs) | Preparation de recepteurs membranaires a partir de baculovirus extracellulaires |
WO2000075314A1 (fr) | 1999-06-02 | 2000-12-14 | Chugai Research Institute For Molecular Medicine, Inc. | Proteine receptrice d'hemopoietine |
WO2003104453A1 (ja) | 2002-06-05 | 2003-12-18 | 中外製薬株式会社 | 抗体作製方法 |
WO2005054467A1 (ja) | 2003-12-03 | 2005-06-16 | Chugai Seiyaku Kabushiki Kaisha | 哺乳類βアクチンプロモーターを利用した発現系 |
WO2006070286A2 (en) * | 2004-12-28 | 2006-07-06 | Innate Pharma S.A. | Monoclonal antibodies against nkg2a |
Non-Patent Citations (72)
Title |
---|
"Heterogeneity of Monoclonal Antibodies", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 97, no. 7, pages 2426 - 2447 |
ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 10 |
ANAL BIOCHEM., vol. 360, no. 1, 1 January 2007 (2007-01-01), pages 75 - 83 |
ANN HEMATOL., vol. 76, no. 6, June 1998 (1998-06-01), pages 231 - 48 |
BETTER ET AL., SCIENCE, vol. 240, 1988, pages 1041 - 1043 |
BETTER, M.; HORWITZ, A. H., METHODS ENZYMOL., vol. 178, 1989, pages 476 - 496 |
BETTER, M.; HORWITZ, A. H., METHODS IN ENZYMOLOGY, vol. 178, 1989, pages 476 - 496 |
BIOCHEM. BIOPHYS. RES. COMMUN., vol. 228, 1996, pages 838 - 45 |
BIRD, R. E. ET AL., TIBTECH, vol. 9, 1991, pages 132 - 137 |
BIRD, R. E.; WALKER, B. W., TRENDS BIOTECHNOL., vol. 9, 1991, pages 132 - 137 |
CANCER RES., vol. 53, no. 4, 15 February 1993 (1993-02-15), pages 851 - 6 |
CHIRINO AJ. ET AL.: "Minimizing the immunogenicity of protein therapeutics", DRUG DISCOV. TODAY, vol. 9, no. 2, 2004, pages 82 - 90, XP002395255 * |
CO, M. S. ET AL., J. IMMUNOL., vol. 152, 1994, pages 2968 - 2976 |
CO, M.S. ET AL., J. IMMUNOL., vol. 152, 1994, pages 2968 - 2976 |
DALBADIE-MCFARLAND, G. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 79, 1982, pages 6409 - 13 |
DILLON SR. ET AL.: "Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice", NAT. IMMUNOL., vol. 5, no. 7, 2004, pages 752 - 760, XP002407998 * |
DIVEU C. ET AL.: "GPL, a novel cytokine receptor related to GP130 and leukemia inhibitory factor receptor", J. BIOL. CHEM., vol. 278, no. 50, 2003, pages 49850 - 49859, XP002475880 * |
EUR J IMMUNOL., vol. 29, no. 8, August 1999 (1999-08-01), pages 2613 - 24 |
EWERT S. ET AL.: "Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering", METHODS, vol. 34, no. 2, 2004, pages 184 - 199, XP008133067 * |
FASEB J., vol. 6, 1992, pages 2422 - 2427 |
HANES J. ET AL.: "Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display", NAT. BIOTECHNOL., vol. 18, no. 12, 2000, pages 1287 - 1292, XP001121946 * |
HASHIMOTO-GOTOH, T; MIZUNO, T; OGASAHARA, Y; NAKAGAWA, M.: "An oligodeoxyribonucleotide-directed dual amber method for site-directed mutagenesis", GENE, vol. 152, 1995, pages 271 - 275 |
HOLLIGER P ET AL., PROC. NATL ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448 |
HOPP, T. P. ET AL., BIOTECHNOLOGY, vol. 6, 1988, pages 1204 - 1210 |
HUDSON ET AL., J IMMUNOL. METHODS, vol. 231, 1999, pages 177 - 189 |
HUSTON, J. S. ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 85, 1988, pages 5879 - 5883 |
INT. IMMUNOL., vol. 18, no. 12, December 2006 (2006-12-01), pages 1759 - 69 |
J ALLERGY CLIN IMMUNOL., vol. 117, no. 2, February 2006 (2006-02-01), pages 418 - 25 |
J BIOL CHEM, vol. 277, 2002, pages 16831 - 6 |
J BIOL CHEM, vol. 278, 2003, pages 49850 - 9 |
J BIOL CHEM., vol. 283, no. 23, 6 June 2008 (2008-06-06), pages 16206 - 15 |
J PHARM SCI., vol. 97, no. 4, April 2008 (2008-04-01), pages 1414 - 26 |
J. BIOL. CHEM., vol. 282, no. 3, 19 January 2007 (2007-01-19), pages 1709 - 17 |
J. EXP. MED., vol. 180, no. 6, 1994, pages 2377 - 2381 |
J. IMMUNOL., vol. 169, no. 9, 1 November 2002 (2002-11-01), pages 5171 - 80 |
J. IMMUNOL., vol. 176, no. 1, 1 January 2006 (2006-01-01), pages 346 - 56 |
KARLIN; ALTSCHUL, PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 5G73 - 7 |
KOHLER, G.; MILSTEIN, C., METHODS ENZYMOL., vol. 73, 1981, pages 3 - 46 |
KOHLER. G.; MILSTEIN, C., METHODS ENZYMOL., vol. 73, 1981, pages 3 - 46 |
KRAMER W; FRITZ HJ: "Oligonucleotide-directed construction of mutations via gapped duplex DNA Methods", ENZYMOL., vol. 154, 1987, pages 350 - 367 |
KRAMER, W; DRUTSA, V; JANSEN, HW; KRAMER, B; PFLUGFELDER, M; FRITZ, HJ: "The gapped duplex DNA approach to oligonucleotide-directed mutation construction", NUCLEIC ACIDS RES., vol. 12, 1984, pages 9441 - 9456 |
KUNKEL, TA: "Rapid and efficient site-specific mutagenesis without phenotypic selection", PROC NATL ACAD SCI USA., vol. 82, 1985, pages 488 - 492 |
LAMOYI, E., METHODS ENZYMOL., vol. 121, 1986, pages 652 - 663 |
LAMOYI, E., METHODS IN ENZYMOLOGY, vol. 121, 1989, pages 652 - 663 |
LANGER ET AL., J. BIOMED. MATER. RES., vol. 15, 1981, pages 167 - 277 |
LANGER, CHEM. TECH., vol. 12, 1982, pages 98 - 105 |
LEI, S. P. ET AL., J. BACTERIAL., vol. 169, 1987, pages 4379 |
MARK, D. F. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 5662 - 6 |
METHODS, vol. 34, no. 4, December 2004 (2004-12-01), pages 468 - 75 |
MIZUSHIMA ET AL., NUCLEIC ACIDS RES., vol. 18, 1990, pages 5322 |
MULLIGAN ET AL., NATURE, vol. 277, 1979, pages 108 |
NAT BIOTECHNOL., vol. 25, no. 12, December 2007 (2007-12-01), pages 1369 - 72 |
NAT IMMUNOL, vol. 5, 2004, pages 752 - 60 |
NAT REV IMMUNOL., vol. 7, no. 9, September 2007 (2007-09-01), pages 715 - 25 |
NAT. BIOTECHNOL., vol. 25, no. 12, December 2007 (2007-12-01), pages 1369 - 72 |
NUCLEIC ACIDS. RES., vol. 18, no. 17, 1990, pages 5322 |
PACE ET AL., PROTEIN SCIENCE, vol. 4, 1995, pages 2411 - 2423 |
PLUCKTHUN, A.; SKERRA, A., METHODS ENZYMOL., vol. 178, 1989, pages 497 - 515 |
PLUECKTHUN, A.; SKERRA, A., METHODS IN ENZYMOLOGY, vol. 178, 1989, pages 476 - 496 |
PROC. NATL. ACAD. SCI. U.S.A., vol. 99, no. 26, 2002, pages 16899 - 16903 |
PROC. NATL. ACAD. SCI. USA., vol. 103, no. 49, 5 December 2006 (2006-12-05), pages 18709 - 14 |
PROTEIN ENGINEERING, vol. 9, no. 3, 1996, pages 299 - 305 |
ROUSSEAUX, J. ET AL., METHODS ENZYMOL., vol. 121, 1986, pages 663 - 669 |
ROUSSEAUX, J. ET AL., METHODS IN ENZYMOLOGY, vol. 121, 1989, pages 663 - 669 |
SATO, K. ET AL., CANCER RES., vol. 53, 1993, pages 851 - 856 |
See also references of EP2236604A4 |
SIDMAN ET AL., BIOPOLYMERS, vol. 22, 1983, pages 547 - 56 |
TAN PH. ET AL.: "Engineering the isoelectric point of a renal cell carcinoma targeting antibody greatly enhances scFv solubility", IMMUNOTECHNOLOGY, vol. 4, no. 2, 1998, pages 107 - 114, XP004153635 * |
WANG, A. ET AL., SCIENCE, vol. 224, 1984, pages 1431 - 3 |
WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546 |
ZOLLER, M. J.; SMITH, M., NUCLEIC ACIDS RES., vol. 10, 1982, pages 6487 - 500 |
ZOLLER, MJ; SMITH, M.: "Oligonucleotide-directed mutagenesis of DNA fragments cloned into M13 vectors", METHODS ENZYMOL., vol. 100, 1983, pages 468 - 500 |
Cited By (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11168344B2 (en) | 2005-03-31 | 2021-11-09 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
US10011858B2 (en) | 2005-03-31 | 2018-07-03 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
US10934344B2 (en) | 2006-03-31 | 2021-03-02 | Chugai Seiyaku Kabushiki Kaisha | Methods of modifying antibodies for purification of bispecific antibodies |
US11046784B2 (en) | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
US9670269B2 (en) | 2006-03-31 | 2017-06-06 | Chugai Seiyaku Kabushiki Kaisha | Methods of modifying antibodies for purification of bispecific antibodies |
US9028821B2 (en) | 2006-06-08 | 2015-05-12 | Chugai Seiyaku Kabushiki Kaisha | Method of treating an inflammatory disease comprising administering an NR 10 antibody antagonist |
US9745378B2 (en) | 2006-06-08 | 2017-08-29 | Chugai Seiyaku Kabushiki Kaisha | Antibodies that bind to cytokine receptor NR10 |
US11248053B2 (en) | 2007-09-26 | 2022-02-15 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
US9828429B2 (en) | 2007-09-26 | 2017-11-28 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
US9688762B2 (en) | 2007-09-26 | 2017-06-27 | Chugai Sciyaku Kabushiki Kaisha | Modified antibody constant region |
US11332533B2 (en) | 2007-09-26 | 2022-05-17 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant region |
US9096651B2 (en) | 2007-09-26 | 2015-08-04 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
EP3415529A1 (en) * | 2007-09-26 | 2018-12-19 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant region |
US9399680B2 (en) | 2007-12-05 | 2016-07-26 | Chugai Seiyaku Kabushiki Kaisha | Nucleic acids encoding anti-NR10 antibodies |
CN101952318A (zh) * | 2007-12-05 | 2011-01-19 | 中外制药株式会社 | 抗nr10抗体及其应用 |
CN101952318B (zh) * | 2007-12-05 | 2014-07-09 | 中外制药株式会社 | 抗nr10抗体及其应用 |
US8431127B2 (en) | 2007-12-05 | 2013-04-30 | Chugai Seiyaku Kabushiki Kaisha | Method for treating pruritus comprising administering an NR10 antagonist |
US10472623B2 (en) | 2008-04-11 | 2019-11-12 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding two or more antigen molecules repeatedly |
US11359194B2 (en) | 2008-04-11 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding two or more antigen molecules repeatedly |
US9868948B2 (en) | 2008-04-11 | 2018-01-16 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
US11371039B2 (en) | 2008-04-11 | 2022-06-28 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
US9890377B2 (en) | 2008-04-11 | 2018-02-13 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
US8562991B2 (en) | 2008-09-26 | 2013-10-22 | Chugai Seiyaku Kabushiki Kaisha | Antibody molecules that bind to IL-6 receptor |
US10662245B2 (en) | 2008-09-26 | 2020-05-26 | Chugai Seiyaku Kabushiki Kaisha | Methods of reducing IL-6 activity for disease treatment |
EP2354161A4 (en) * | 2008-12-05 | 2013-01-02 | Chugai Pharmaceutical Co Ltd | ANTI-NR10 ANTIBODIES AND CORRESPONDING USE |
EP2949672A1 (en) * | 2008-12-05 | 2015-12-02 | Chugai Seiyaku Kabushiki Kaisha | Anti-nr10 antibody, and use thereof |
JP5139517B2 (ja) * | 2008-12-05 | 2013-02-06 | 中外製薬株式会社 | 抗nr10抗体、およびその利用 |
JPWO2010064697A1 (ja) * | 2008-12-05 | 2012-05-10 | 中外製薬株式会社 | 抗nr10抗体、およびその利用 |
EP2354161A1 (en) * | 2008-12-05 | 2011-08-10 | Chugai Seiyaku Kabushiki Kaisha | Anti-nr10 antibody, and use thereof |
US10253091B2 (en) | 2009-03-19 | 2019-04-09 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
US9228017B2 (en) | 2009-03-19 | 2016-01-05 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
US10066018B2 (en) | 2009-03-19 | 2018-09-04 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
US10150808B2 (en) | 2009-09-24 | 2018-12-11 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant regions |
EP3275898A1 (en) | 2009-11-05 | 2018-01-31 | Osaka University | Therapeutic agent for autoimmune diseases or allergy, and method for screening for the therapeutic agent |
WO2011055550A1 (ja) | 2009-11-05 | 2011-05-12 | 国立大学法人大阪大学 | 自己免疫疾患又はアレルギー治療剤とそのスクリーニング方法 |
US11612562B2 (en) | 2010-01-20 | 2023-03-28 | Chugai Seiyaku Kabushiki Kaisha | Solution preparation containing stabilized antibody |
EP3892292A2 (en) | 2010-01-20 | 2021-10-13 | Chugai Seiyaku Kabushiki Kaisha | Stabilized antibody-containing liquid formulations |
WO2011090088A1 (ja) | 2010-01-20 | 2011-07-28 | 中外製薬株式会社 | 安定化抗体含有溶液製剤 |
US10022319B2 (en) | 2010-01-20 | 2018-07-17 | Chugai Seiyaku Kabushiki Kaisha | Stabilized antibody-containing liquid formulations |
EP3378486A2 (en) | 2010-01-20 | 2018-09-26 | Chugai Seiyaku Kabushiki Kaisha | Stabilized antibody-containing liquid formulations |
US10435458B2 (en) | 2010-03-04 | 2019-10-08 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variants with reduced Fcgammar binding |
JP5889181B2 (ja) * | 2010-03-04 | 2016-03-22 | 中外製薬株式会社 | 抗体定常領域改変体 |
JPWO2011108714A1 (ja) * | 2010-03-04 | 2013-06-27 | 中外製薬株式会社 | 抗体定常領域改変体 |
WO2011143318A3 (en) * | 2010-05-11 | 2012-01-05 | Aveo Pharmaceuticals, Inc. | Anti-fgfr2 antibodies |
US8481688B2 (en) | 2010-05-11 | 2013-07-09 | Aveo Pharmaceuticals, Inc. | Anti-FGFR2 antibodies |
US11891434B2 (en) | 2010-11-30 | 2024-02-06 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
US20130295613A1 (en) * | 2010-12-28 | 2013-11-07 | Chugai Seiyaku Kabushiki Kaisha | Animal cell culturing method |
CN103282509A (zh) * | 2010-12-28 | 2013-09-04 | 中外制药株式会社 | 动物细胞的培养方法 |
WO2012091124A1 (ja) | 2010-12-28 | 2012-07-05 | 中外製薬株式会社 | 動物細胞の培養方法 |
JP6001456B2 (ja) * | 2010-12-28 | 2016-10-05 | 中外製薬株式会社 | 動物細胞の培養方法 |
WO2013012022A1 (ja) | 2011-07-19 | 2013-01-24 | 中外製薬株式会社 | アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤 |
EP3235557A1 (en) | 2011-09-01 | 2017-10-25 | Chugai Seiyaku Kabushiki Kaisha | Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration |
WO2013031237A1 (en) | 2011-09-01 | 2013-03-07 | Chugai Seiyaku Kabushiki Kaisha | Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration |
US11124576B2 (en) | 2013-09-27 | 2021-09-21 | Chungai Seiyaku Kabushiki Kaisha | Method for producing polypeptide heteromultimer |
WO2015099165A1 (ja) | 2013-12-27 | 2015-07-02 | 中外製薬株式会社 | 等電点の低い抗体の精製方法 |
EP4056993A1 (en) | 2014-08-20 | 2022-09-14 | Chugai Seiyaku Kabushiki Kaisha | Method for measuring viscosity of protein solution |
US10774148B2 (en) | 2015-02-27 | 2020-09-15 | Chugai Seiyaku Kabushiki Kaisha | Composition for treating IL-6-related diseases |
US11142587B2 (en) | 2015-04-01 | 2021-10-12 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide hetero-oligomer |
KR20240033097A (ko) | 2015-04-14 | 2024-03-12 | 추가이 세이야쿠 가부시키가이샤 | Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물 |
US11773173B2 (en) | 2015-04-14 | 2023-10-03 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising IL-31 antagonist as active ingredient |
KR20230043246A (ko) | 2015-04-14 | 2023-03-30 | 추가이 세이야쿠 가부시키가이샤 | Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물 |
US10544227B2 (en) | 2015-04-14 | 2020-01-28 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising IL-31 antagonist as active ingredient |
KR20210145295A (ko) | 2015-04-14 | 2021-12-01 | 추가이 세이야쿠 가부시키가이샤 | Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물 |
US11649262B2 (en) | 2015-12-28 | 2023-05-16 | Chugai Seiyaku Kabushiki Kaisha | Method for promoting efficiency of purification of Fc region-containing polypeptide |
JP2019504060A (ja) * | 2016-01-08 | 2019-02-14 | オンコバイオロジクス,インコーポレイティド | モノクローナル抗体のアイソフォームを分離するための方法 |
US11780908B2 (en) | 2016-09-16 | 2023-10-10 | Chugai Seiyaku Kabushiki Kaisha | Anti-dengue virus antibodies, polypeptides containing variant FC regions, and methods of use |
US10604561B2 (en) | 2016-09-16 | 2020-03-31 | Chugai Seiyaku Kabushiki Kaisha | Anti-dengue virus antibodies, polypeptides containing variant Fc regions, and methods of use |
US10844113B2 (en) | 2016-09-16 | 2020-11-24 | Chugai Seiyaku Kabushiki Kaisha | Anti-dengue virus antibodies, polypeptides containing variant Fc regions, and methods of use |
US11851486B2 (en) | 2017-05-02 | 2023-12-26 | National Center Of Neurology And Psychiatry | Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils |
US11891432B2 (en) | 2018-03-15 | 2024-02-06 | Chugai Seiyaku Kabushiki Kaisha | Anti-dengue virus antibodies having cross-reactivity to Zika virus and methods of use |
WO2019225568A1 (ja) | 2018-05-21 | 2019-11-28 | 中外製薬株式会社 | ガラス容器に封入された凍結乾燥製剤 |
WO2019230725A1 (ja) | 2018-05-28 | 2019-12-05 | 中外製薬株式会社 | 充填ノズル |
JP2021169448A (ja) * | 2019-11-20 | 2021-10-28 | 中外製薬株式会社 | 抗体含有製剤 |
KR20220098046A (ko) | 2019-11-20 | 2022-07-08 | 추가이 세이야쿠 가부시키가이샤 | 항체 함유 제제 |
US11260125B2 (en) | 2019-11-20 | 2022-03-01 | Chugai Seiyaku Kabushiki Kaisha | Anti-IL31RA antibody-containing formulations |
WO2021100794A1 (ja) | 2019-11-20 | 2021-05-27 | 中外製薬株式会社 | 抗体含有製剤 |
JP6845973B1 (ja) * | 2019-11-20 | 2021-03-24 | 中外製薬株式会社 | 抗体含有製剤 |
JP2021091704A (ja) * | 2019-11-20 | 2021-06-17 | 中外製薬株式会社 | 抗体含有製剤 |
US11723976B2 (en) | 2019-11-20 | 2023-08-15 | Chugai Seiyaku Kabushiki Kaisha | Methods of administering anti-IL31A antibody-containing formulations |
KR20210064112A (ko) | 2019-11-20 | 2021-06-02 | 추가이 세이야쿠 가부시키가이샤 | 항체 함유 제제 |
WO2022025030A1 (ja) | 2020-07-28 | 2022-02-03 | 中外製薬株式会社 | 新規改変型抗体を含む、針シールドを備えた針付プレフィルドシリンジ製剤 |
WO2022049614A1 (ja) | 2020-09-01 | 2022-03-10 | 中外製薬株式会社 | Il-31アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び/又は治療用医薬組成物 |
WO2023058723A1 (ja) | 2021-10-08 | 2023-04-13 | 中外製薬株式会社 | プレフィルドシリンジ製剤の調製方法 |
JPWO2023120561A1 (ja) * | 2021-12-22 | 2023-06-29 | ||
WO2023120561A1 (ja) * | 2021-12-22 | 2023-06-29 | 中外製薬株式会社 | 生物活性が低下した抗体バリアント |
KR20240117039A (ko) | 2021-12-22 | 2024-07-31 | 추가이 세이야쿠 가부시키가이샤 | 생물 활성이 저하된 항체 배리언트 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009072604A1 (ja) | 抗nr10抗体、およびその利用 | |
WO2005074375A3 (en) | Heparanase inhibitors and uses thereof | |
WO2006078287A3 (en) | Pde4b inhibitors and uses therefor | |
WO2010060937A3 (en) | Pharmaceutical combination comprising a hsp 90 inhibitor and a mtor inhibitor | |
WO2007127263A3 (en) | Therapeutic uses of urolithins | |
MX2009006536A (es) | Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales. | |
BRPI0818366A2 (pt) | Composto, pró-droga, medicamento, método inibidor de faah, métodos de profilaxia ou tratamento para ansiedade, ou depressão, ou de alívio da dor, e de profilaxia ou tratamento para dor inflamatória ou dor neuropática, e, uso do composto. | |
WO2007115305A3 (en) | Oral dosage forms including an antiplatelet agent and an acid inhibitor | |
WO2007038551A3 (en) | Use of ibudilast for treating drug and behavioral addictions | |
TNSN08400A1 (en) | Organic compounds and their uses | |
WO2007117971A3 (en) | Ocular allergy treatments | |
NL1028599A1 (nl) | Verbindingen voor de behandeling van ziekten. | |
WO2007051785A3 (en) | Use of sdf-1 for the treatment and/or prevention of neurological diseases | |
WO2007121125A3 (en) | Hcv inhibitors | |
WO2002060374A3 (en) | Benz-1,3-azole derivatives and their uses as heparanase inhibitors | |
WO2009041663A1 (ja) | 皮膚疾患の予防及び/または治療剤 | |
WO2008067982A3 (en) | Use of carrageenan for treating rhinovirus infections | |
WO2007106915A3 (en) | Antibodies to egfl7 and methods for their use | |
TNSN08496A1 (en) | Aminothiazoles and their uses | |
MY154715A (en) | Anti-nr10 antibody and use thereof | |
WO2006089664A3 (de) | Heterocyclylamid-substituierte imidazole | |
WO2009103959A3 (en) | Histidine and/or histidine derivative for the treatment of inflammatory skin diseases | |
MX2011009100A (es) | Anticuerpo humanizado pcrv que tiene actividad anti-pseudomonal. | |
WO2008033389A3 (en) | Macrocyclic hcv inhibitors and their uses | |
WO2009018551A3 (en) | Therapeutic compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880126539.4 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08857126 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009544736 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3945/DELNP/2010 Country of ref document: IN Ref document number: 12010501289 Country of ref document: PH Ref document number: MX/A/2010/006096 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2708532 Country of ref document: CA Ref document number: 2008332271 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2008332271 Country of ref document: AU Date of ref document: 20081205 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20107014698 Country of ref document: KR Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2008857126 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010127292 Country of ref document: RU Ref document number: 2008857126 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PI 2010002565 Country of ref document: MY |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12745781 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0821110 Country of ref document: BR Kind code of ref document: A2 Effective date: 20100604 |